Streetbeat News

EPIX

ESSA Pharma Inc.

https://www.essapharma.com

Industry

Biotechnology

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Open

1.73

Mkt cap

76M

Volume

60K

High

1.76

P/E Ratio

-2.49

52-wk high

9.92

Low

1.72

Div yield

N/A

52-wk low

1.40

A class action lawsuit has been filed against ESSA Pharma Inc. (NASDAQ:EPIX) for potential recovery under federal securities laws. Investors who suffered losses are encouraged to join the suit.

Portfolio Pulse from

February 23, 2025 | 3:30 am

Rosen Law Firm is inviting investors who purchased ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023, and October 31, 2024, to join a securities fraud lawsuit. The deadline for lead plaintiff applications is March 25, 2025.

Portfolio Pulse from

February 22, 2025 | 3:45 pm

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ESSA Pharma Inc. and certain officers, offering investors with substantial losses the opportunity to lead the lawsuit.

Portfolio Pulse from

February 21, 2025 | 9:15 pm

A class action lawsuit has been filed against ESSA Pharma Inc. (NASDAQ:EPIX) with a deadline of March 25, 2025, for investors to join. The lawsuit is related to potential recovery under federal securities laws.

Portfolio Pulse from

February 21, 2025 | 8:45 pm

Levi & Korsinsky has notified shareholders of ESSA Pharma Inc. (NASDAQ:EPIX) about a class action lawsuit and an upcoming deadline. Investors who suffered losses can learn about potential recovery under federal securities laws.

Portfolio Pulse from

February 21, 2025 | 1:00 am

A class action lawsuit has been filed against ESSA Pharma Inc. (EPIX) by The Gross Law Firm, seeking recovery for investors. Shareholders are encouraged to contact the firm for more information.

Portfolio Pulse from

February 20, 2025 | 6:30 pm

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ESSA Pharma Inc. (NASDAQ:EPIX) for alleged violations of federal securities laws. The lawsuit targets investors who acquired ESSA securities between December 12, 2023, and October 31, 2024.

Portfolio Pulse from

February 20, 2025 | 3:15 pm

The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX) regarding a pending class action lawsuit. Shareholders who purchased EPIX shares during the specified class period are encouraged to contact the firm for potential lead plaintiff appointment.

Portfolio Pulse from

February 20, 2025 | 11:00 am

A class action lawsuit has been filed against ESSA Pharma Inc. (NASDAQ:EPIX) for potential securities law violations. Investors who suffered losses are encouraged to join the suit by March 25, 2025.

Portfolio Pulse from

February 20, 2025 | 4:30 am

Levi & Korsinsky is inviting investors who lost money on ESSA Pharma Inc. (EPIX) to join a class action lawsuit for potential recovery under federal securities laws.

Portfolio Pulse from

February 19, 2025 | 11:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.